Fragmenting the S100B-p53 Interaction: Combined Virtual/Biophysical Screening Approaches to Identify Ligands

被引:13
作者
Agamennone, Mariangela [2 ]
Cesari, Lucia [1 ,3 ]
Lalli, Daniela [4 ,5 ]
Turlizzi, Elisa [6 ]
Del Conte, Rebecca [4 ]
Turano, Paola [4 ,5 ]
Mangani, Stefano [3 ]
Padova, Alessandro [1 ]
机构
[1] Siena Biotech SpA, Drug Design Unit, Mol Informat Dept, I-53100 Siena, Italy
[2] Univ G DAnnunzio, Dipartimento Sci Farm, I-66013 Chieti, Italy
[3] Univ Siena, Dipartimento Chim, I-53100 Siena, Italy
[4] Univ Florence, Magnet Resonance Ctr CERM, I-50019 Sesto Fiorentino, Italy
[5] Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy
[6] Siena Biotech SpA, MET Profiling Unit, Screening & Technol Dept, I-53100 Siena, Italy
关键词
fragment-based drug design; NMR spectroscopy; protein-protein interactions; X-ray diffraction; NUCLEAR-MAGNETIC-RESONANCE; S100; FAMILY; TERMINAL DOMAIN; SMALL MOLECULES; DRUG DISCOVERY; PROTEIN; BINDING; NMR; P53; IDENTIFICATION;
D O I
10.1002/cmdc.200900393
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
S100B contributes to cell proliferation by binding the C terminus of p53 and inhibiting its tumor suppressor function. The use of multiple computational approaches to screen fragment libraries targeting the human S100B-p53 interaction site is reported. This in silico screening led to the identification of 280 novel prospective ligands. NMR spectroscopic experiments revealed specific binding at the p53 interaction site for a set of these compounds and confirmed their potential for further rational optimization. The X-ray crystal structure determined for one of the binders revealed key intermolecular interactions, thus paving the way for structure-based ligand optimization.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 58 条
[1]
Fragment docking to s100 proteins reveals a wide diversity of weak interaction sites [J].
Arendt, Yvonne ;
Bhaumik, Anusarka ;
Del Conte, Rebecca ;
Luchinat, Claudio ;
Mori, Mattia ;
Porcu, Marco .
CHEMMEDCHEM, 2007, 2 (11) :1648-1654
[2]
THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]
CHARACTERIZATION OF THE TUMOR SUPPRESSOR PROTEIN-P53 AS A PROTEIN-KINASE-C SUBSTRATE AND A S100B-BINDING PROTEIN [J].
BAUDIER, J ;
DELPHIN, C ;
GRUNWALD, D ;
KHOCHBIN, S ;
LAWRENCE, JJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) :11627-11631
[4]
BENN A, 2006, MED CHEM GORD RES C
[5]
Fragment-based lead discovery: leads by design [J].
Carr, RAE ;
Congreve, M ;
Murray, CW ;
Rees, DC .
DRUG DISCOVERY TODAY, 2005, 10 (14) :987-992
[6]
Divalent metal ion complexes of S100B in the absence and presence of pentamidine [J].
Charpentier, Thomas H. ;
Wilder, Paul T. ;
Liriano, Melissa A. ;
Varney, Kristen M. ;
Pozharski, Edwin ;
MacKerell, Alexander D., Jr. ;
Coop, Andrew ;
Toth, Eric A. ;
Weber, David J. .
JOURNAL OF MOLECULAR BIOLOGY, 2008, 382 (01) :56-73
[7]
Small Molecules Bound to Unique Sites in the Target Protein Binding Cleft of Calcium-Bound S100B As Characterized by Nuclear Magnetic Resonance and X-ray Crystallography [J].
Charpentier, Thomas H. ;
Wilder, Paul T. ;
Liriano, Melissa A. ;
Varney, Kristen M. ;
Zhong, Shijun ;
Coop, Andrew ;
Pozharski, Edwin ;
MacKerell, Alexander D., Jr. ;
Toth, Eric A. ;
Weber, David J. .
BIOCHEMISTRY, 2009, 48 (26) :6202-6212
[8]
A rule of three for fragment-based lead discovery? [J].
Congreve, M ;
Carr, R ;
Murray, C ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2003, 8 (19) :876-877
[9]
WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability [J].
Dalvit, C ;
Fogliatto, G ;
Stewart, A ;
Veronesi, M ;
Stockman, B .
JOURNAL OF BIOMOLECULAR NMR, 2001, 21 (04) :349-359
[10]
Exploring experimental sources of multiple protein conformations in structure-based drug design [J].
Damm, Kelly L. ;
Carlson, Heather A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (26) :8225-8235